Abstract Search

Abstract unavailable....

0 shares

ea0090p656 | Endocrine-related Cancer | ECE2023

Management of NENs with SSTR2-antagonist: how close are we to a clinical solution? The first results of the TECANT study: Novel 99m-Tc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms – a feasibility study

Hubalewska-Dydejczyk Alicja , Decristoforo Clemens , Kolenc Petra , Mikolajczak Renata , Ležaić Luka , Suden Andrej , Garnuszek Piotr , Simoncic Urban , Virgolini Irene , Trofimiuk-Muldner Malgorzata , Opalinska Marta , Rangger Christine , Glowa Boguslaw , Skorkiewicz Konrad , Fani Melpomeni , Sowa Staszczak Anna , Janota Barbara , Kroselj Marko , Zaletel Katja , Von Guggenberg Elisabeth

Introduction: The management of patients with neuroendocrine neoplasms (NEN) has been revolutionised since the introduction of radiolabelled somatostatin analogues targeting overexpressed somatostatin receptors (SSTR). Accurate assessment of SSTR status of primary focus/metastases is crucial to determine the choice of the treatment method. Recently it has been shown that novel molecular probes, SST2-antagonists, recognize more binding sites in comparison to the wide...

4 shares

ea0049ep1445 | Thyroid (non-cancer) | ECE2017

Theranostic management of medullary thyroid cancer (MTC) with (111In/177Lu) CP04: how close are we to a clinical solution?

Hubalewska-Dydejczyk Alicja , Erba Paola , Decristoforo Clemens , Zaletel Katja , Mikolajczak Renata , Maecke Helmut , Maina-Nock Theodosia , Konijnenberg Mark , Kolenc-Peitl Petra , Trofimiuk-Muldner Malgorzata , Przybylik-Mazurek Elwira , Virgolini Irene , Pawlak Dariusz , de Jong Marion , Froberg Alide C , Rangger Christine , Goebel Georg , Scarpa Lorenza , Skorkiewicz Konrad , Lezaic Luka , Garnuszek Pirotr , Sowa-Staszczak Anna , Nock Berthold A , Bergant Damijan , Rep Sebastijan , Glowa Boguslaw

Effective targeted therapy for advanced endocrine malignancies is a goal of modern endocrinology. We herein present promising results of the first phase of clinical part of European project (Gran-T-MTC) aimed to assess the safety of gastrin analogue CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) i.v. administration in dose (50 μg) useful for translation to 177In-CP04 for PRRT. CP04 has been selected for MTC therapy based on a high CCK-2 receptor...

0 shares

Endocrine Abstracts

PET based somatostatin receptor imaging of NET

Management of NENs with SSTR2-antagonist: how close are we to a clinical solution? The first results of the TECANT study: Novel 99m-Tc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms – a feasibility study

Theranostic management of medullary thyroid cancer (MTC) with (111In/177Lu) CP04: how close are we to a clinical solution?

BiosciAbstracts